We are updating our Privacy Policy and Terms and Conditions to help you clearly understand how your personal information is collected, stored and managed. Learn More
Menu Back toGene-Therapy-Advances-in-Translating-Technology

DIA 2018 Global Annual Meeting

The DIA 2018 Global Annual Meeting brings together thousands of innovators from around the globe.

Gene Therapy: Advances in Translating Technology

    Session Chair(s)
      Peter W. Marks, MD, PhD

      Peter W. Marks, MD, PhD

      • Director, Center for Biologics Evaluation and Research
      • FDA, United States
    Gene therapy is now a reality in the clinic with additional products working toward regulatory approval. Advances in gene editing are expanding the boundaries of what was previously thought possible for gene therapy on somatic cells. However, challenges remain in translating scientific advances into clinical progress. This session will discuss/review recent advances in the field, discuss the existing regulatory framework, and provide perspectives from several different sponsors developing products.
    Learning Objective : Identify recent advances in the field of gene therapy; Discuss the existing regulatory framework.
      Terence  Flotte, MD

      How Has Adeno-Associated Virus (AAV) Evolved?

      Terence Flotte, MD

      • Dean, Provost and Executive Deputy Chancellor
      • University of Massachusetts Medical School, United States
      David  Davidson, MD

      Update on the Development of the LentiGlobin Program

      David Davidson, MD

      • Chief Medical Officer
      • bluebird bio, Inc., United States
      Eva  Essig

      Past and Recent Landscape of Genome Editing, Technologies, Advances, and Safety

      Eva Essig

      • Vice President, Regulatory Affairs
      • Intellia Therapeutics, Inc., United States
      Michael  Havert, PhD


      Michael Havert, PhD

      • Biologist/CMC Reviewer, Gene Therapy Branch, OTAT, CBER
      • FDA, United States